<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36347843</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression.</ArticleTitle><Pagination><StartPage>6733</StartPage><MedlinePgn>6733</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6733</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-34526-9</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, involving neuroinflammation and T cell infiltration in the central nervous system. However, the contribution of T cell responses to the pathology of the disease is not fully understood. Here we show, by flow cytometric analysis of blood and cerebrospinal fluid (CSF) samples of a cohort of 89 newly diagnosed ALS patients in Stockholm, Sweden, that T cell phenotypes at the time of diagnosis are good predictors of disease outcome. High frequency of CD4<sup>+</sup>FOXP3<sup>-</sup> effector T cells in blood and CSF is associated with poor survival, whereas high frequency of activated regulatory T (Treg) cells and high ratio between activated and resting Treg cells in blood are associated with better survival. Besides survival, phenotypic profiling of T cells could also predict disease progression rate. Single cell transcriptomics analysis of CSF samples shows clonally expanded CD4<sup>+</sup> and CD8<sup>+</sup> T cells in CSF, with characteristic gene expression patterns. In summary, T cell responses associate with and likely contribute to disease progression in ALS, supporting modulation of adaptive immunity as a viable therapeutic option.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yazdani</LastName><ForeName>Solmaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Seitz</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cui</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovik</LastName><ForeName>Anik&#xf3;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Lu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7467-6992</Identifier><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piehl</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-8329-5219</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology clinic, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawitan</LastName><ForeName>Yudi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0324-7052</Identifier><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kl&#xe4;ppe</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-5832-038X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology clinic, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Press</LastName><ForeName>Rayomand</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology clinic, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samuelsson</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology clinic, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Trung Nghia</ForeName><Initials>TN</Initials><Identifier Source="ORCID">0000-0001-7945-5750</Identifier><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joly</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westerberg</LastName><ForeName>Lisa S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0003-2943-2192</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evertsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology clinic, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology clinic, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Andersson</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2799-6349</Identifier><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. john.andersson@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3310-6456</Identifier><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. fang.fang@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36347843</ArticleId><ArticleId IdType="pmc">PMC9643478</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34526-9</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-34526-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr. Opin. Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Peripheral and central nervous system immune response crosstalk in amyotrophic lateral sclerosis. Front. Neurosci. 14, 575 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308438</ArticleId><ArticleId IdType="pubmed">32612503</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 1993;50:30&#x2013;36. doi: 10.1001/archneur.1993.00540010026013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1993.00540010026013</ArticleId><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr. Mol. Med. 2011;11:246&#x2013;254. doi: 10.2174/156652411795243450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE. 2007;2:e1205. doi: 10.1371/journal.pone.0001205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J. Neuroimmune Pharm. 2009;4:389&#x2013;398. doi: 10.1007/s11481-009-9171-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-009-9171-5</ArticleId><ArticleId IdType="pubmed">19731042</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293&#x2013;1314. doi: 10.1093/brain/awr074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl Acad. Sci. USA. 2008;105:17913&#x2013;17918. doi: 10.1073/pnas.0804610105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804610105</ArticleId><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl Acad. Sci. USA. 2008;105:15558&#x2013;15563. doi: 10.1073/pnas.0807419105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Naor S, et al. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J. Neurol. 2009;256:1228&#x2013;1235. doi: 10.1007/s00415-009-5097-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5097-3</ArticleId><ArticleId IdType="pubmed">19280101</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, et al. Regulatory T&#x2010;lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Camu W, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2020;59:102844. doi: 10.1016/j.ebiom.2020.102844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102844</ArticleId><ArticleId IdType="pmc">PMC7502670</ArticleId><ArticleId IdType="pubmed">32651161</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafflick D, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat. Commun. 2020;11:1&#x2013;14. doi: 10.1038/s41467-019-14118-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14118-w</ArticleId><ArticleId IdType="pmc">PMC6959356</ArticleId><ArticleId IdType="pubmed">31937773</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav., Immun. 2011;25:1025&#x2013;1035. doi: 10.1016/j.bbi.2010.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannelli I, Heath P, Shaw PJ, Kirby J. The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:435&#x2013;444. doi: 10.1080/21678421.2020.1752246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1752246</ArticleId><ArticleId IdType="pubmed">32484719</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid, S. I., Ampie, L., Kelly, R., Ladha, S. S. &amp; Dardis, C. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front. Neurol. 8, 486 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622209</ArticleId><ArticleId IdType="pubmed">28993751</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol. Res. Int. 2011;2011:e497080. doi: 10.1155/2011/497080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/497080</ArticleId><ArticleId IdType="pmc">PMC3150148</ArticleId><ArticleId IdType="pubmed">21826267</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanedo-Vazquez D, Bosque-Varela P, Sainz-Pelayo A, Riancho J. Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration. J. Neurol. 2019;266:27&#x2013;36. doi: 10.1007/s00415-018-8919-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8919-3</ArticleId><ArticleId IdType="pubmed">29845377</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson J, Stefanova I, Stephens GL, Shevach EM. CD4+CD25+ regulatory T cells are activated in vivo by recognition of self. Int. Immunol. 2007;19:557&#x2013;566. doi: 10.1093/intimm/dxm021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxm021</ArticleId><ArticleId IdType="pubmed">17369190</ArticleId></ArticleIdList></Reference><Reference><Citation>Szymczak-Workman AL, Workman CJ, Vignali DAA. Cutting edge: regulatory T cells do not require stimulation through their TCR to suppress. J. Immunol. 2009;182:5188&#x2013;5192. doi: 10.4049/jimmunol.0803123.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803123</ArticleId><ArticleId IdType="pmc">PMC2745156</ArticleId><ArticleId IdType="pubmed">19380762</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, G&#xfc;nther R, Akg&#xfc;n K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci. Rep. 2020;10:5941. doi: 10.1038/s41598-020-62756-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62756-8</ArticleId><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 2010;11:674&#x2013;680. doi: 10.1038/ni.1899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1899</ArticleId><ArticleId IdType="pmc">PMC3249647</ArticleId><ArticleId IdType="pubmed">20644573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, et al. Eomes controls the development of Th17-derived (non-classic) Th1 cells during chronic inflammation. Eur. J. Immunol. 2019;49:79&#x2013;95. doi: 10.1002/eji.201847677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847677</ArticleId><ArticleId IdType="pubmed">30144030</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruarin P, et al. Eomesodermin controls a unique differentiation program in human IL-10 and IFN-&#x3b3; coproducing regulatory T cells. Eur. J. Immunol. 2019;49:96&#x2013;111. doi: 10.1002/eji.201847722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847722</ArticleId><ArticleId IdType="pubmed">30431161</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveney BJE, et al. Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis. Proc. Natl Acad. Sci. USA. 2021;118:e2021818118. doi: 10.1073/pnas.2021818118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2021818118</ArticleId><ArticleId IdType="pmc">PMC7980371</ArticleId><ArticleId IdType="pubmed">33836594</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveney BJE, et al. Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat. Commun. 2015;6:8437. doi: 10.1038/ncomms9437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9437</ArticleId><ArticleId IdType="pmc">PMC4600741</ArticleId><ArticleId IdType="pubmed">26436530</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson, M. P. et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE12, e0182002 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill RB, et al. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Commun. 2020;2:fcaa013. doi: 10.1093/braincomms/fcaa013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa013</ArticleId><ArticleId IdType="pmc">PMC7530830</ArticleId><ArticleId IdType="pubmed">33033799</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3:e242. doi: 10.1212/NXI.0000000000000242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000242</ArticleId><ArticleId IdType="pmc">PMC4897983</ArticleId><ArticleId IdType="pubmed">27308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, et al. The Swedish motor neuron disease quality registry. Amyotroph. Lateral Scler. Frontotemporal Degener. 2018;19:528&#x2013;537. doi: 10.1080/21678421.2018.1497065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1497065</ArticleId><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyara M, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899&#x2013;911. doi: 10.1016/j.immuni.2009.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.03.019</ArticleId><ArticleId IdType="pubmed">19464196</ArticleId></ArticleIdList></Reference><Reference><Citation>RUBIN DB. Inference and missing data. Biometrika. 1976;63:581&#x2013;592. doi: 10.1093/biomet/63.3.581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/63.3.581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin, D. B. An overview of multiple imputation. In Proc. Survey Research Section 79&#x2013;84 (American Statistical Association, 1988).</Citation></Reference><Reference><Citation>Nassiri V, Lovik A, Molenberghs G, Verbeke G. On using multiple imputation for exploratory factor analysis of incomplete data. Behav. Res. Methods. 2018;50:501&#x2013;517. doi: 10.3758/s13428-017-1013-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/s13428-017-1013-4</ArticleId><ArticleId IdType="pubmed">29392587</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavaliunas A, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult. Scler. 2017;23:1233&#x2013;1240. doi: 10.1177/1352458516675039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458516675039</ArticleId><ArticleId IdType="pubmed">27754943</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan, L. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression. Zenodo10.5281/zenodo.6759696 (2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>